Immunohistological expression of oestrogen receptor, progesterone receptor, mammaglobin, human epidermal growth factor receptor 2 and GATA-binding protein 3 in non-small-cell lung cancer.
Adenocarcinoma
/ diagnosis
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ metabolism
Carcinoma, Large Cell
/ diagnosis
Carcinoma, Neuroendocrine
/ diagnosis
Carcinoma, Non-Small-Cell Lung
/ diagnosis
Diagnosis, Differential
Female
GATA3 Transcription Factor
/ metabolism
Humans
Immunohistochemistry
Lung Neoplasms
/ metabolism
Mammaglobin A
/ metabolism
Middle Aged
Receptor, ErbB-2
/ metabolism
Receptors, Progesterone
/ metabolism
Tissue Array Analysis
ER
GATA3
HER2
NSCLC
PgR
lung cancer
mammaglobin
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
20
04
2020
revised:
27
06
2020
accepted:
02
07
2020
pubmed:
8
7
2020
medline:
24
8
2021
entrez:
8
7
2020
Statut:
ppublish
Résumé
Non-small-cell lung cancer (NSCLC) and breast cancer are common entities. Staining for oestrogen receptor (ER), progesterone receptor (PgR), mammaglobin (MAMG) and GATA-binding protein 3 (GATA3) is frequently performed to confirm a mammary origin in the appropriate diagnostic setting. However, comprehensive data on the immunohistological expression of these markers in NSCLC are limited. Therefore, the aim of this study was to analyse a large cohort of NSCLCs and correlate the staining results with clinicopathological variables. A tissue microarray was stained for ER, PgR, MAMG, human epidermal growth factor receptor 2 (HER2), and GATA3, and included 636 adenocarcinomas (ADCs), 536 squamous cell carcinomas (SqCCs), 65 large-cell-carcinomas, 34 pleomorphic carcinomas, and 20 large-cell neuroendocrine carcinomas. HER2 status was determined for immunohistochemically positive cases with chromogenic in-situ hybridisation. Markers with a proportion of ≥5% positive cases in ADC and SqCC were considered for survival analysis. Among ADCs, 62 (10%), 17 (3%), one (<1%), seven (1%), and 49 (8%) cases were positive for ER, PgR, MAMG, HER2, and GATA3, respectively. Among SqCCs, 10 (2%), 14 (3%), two (<1%) and 109 (20%) cases were positive for ER, PgR, HER2, and GATA3, but none of the samples showed positivity for MAMG. ER positivity was associated with ADC, female sex, smaller tumour size, and lower clinical stage. None of the markers had an impact on survival. We report on ER, PgR, MAMG, HER2 and GATA3 expression in a large cohort of NSCLCs. Interpretation of these markers in the differential diagnostic setting should be based on a multimarker panel.
Substances chimiques
Biomarkers, Tumor
0
GATA3 Transcription Factor
0
GATA3 protein, human
0
Mammaglobin A
0
Receptors, Progesterone
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
900-914Informations de copyright
© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd.
Références
Howlader N, Noone AM, Krapcho M et al. SEER cancer statistics review, 1975-2013. Bethesda, MD: National Cancer Institute, 2016. Available at: http://seer.cancer.gov/csr/1975_2013/
Lester SH, David GH. Diagnostic pathology: Breast. 2nd ed. Altona, Canada: Amirsys, 2017;600.
Wu Q, Li J, Zhu S et al. Breast cancer subtypes predict the preferential site of distant metastases: a seer based study. Oncotarget 2017; 8; 27990-27996.
Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N. Engl. J. Med. 2017; 377; 849-861.
Hortobagyi GN, Stemmer SM, Burris HA et al. Ribociclib as first-line therapy for hr-positive, advanced breast cancer. N. Engl. J. Med. 2016; 375; 1738-1748.
Finn RS, Martin M, Rugo HS et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 2016; 375; 1925-1936.
Gown AM, Fulton RS, Kandalaft PL. Markers of metastatic carcinoma of breast origin. Histopathology 2016; 68; 86-95.
O'Brien N, O'Donovan N, Foley D et al. Use of a panel of novel genes for differentiating breast cancer from non-breast tissues. Tumour Biol. 2007; 28; 312-317.
Travis WDBE, Burke AP, Marx A, Nicholson AG. Who classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon, France: IARC Publication, 2015.
Warth A, Muley T, Herpel E et al. Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathology 2012; 61; 1017-1025.
Lisenko K, Leichsenring J, Zgorzelski C et al. Qualitative comparison between carrier-based and classical tissue microarrays. Appl. Immunohistochem. Mol. Morphol. 2017; 25; e74-e79.
Kriegsmann M, Harms A, Longuespee R et al. Role of conventional immunomarkers, hnf4-a, and satb2 in the differential diagnosis of pulmonary and colorectal adenocarcinomas. Histopathology 2018; 72; 997-1006.
Kriegsmann K, Cremer M, Zgorzelski C et al. Agreement of ck5/6, p40, and p63 immunoreactivity in non-small cell lung cancer. Pathology 2019; 51; 240-245.
Kriegsmann M, Muley T, Harms A et al. Differential diagnostic value of cd5 and cd117 expression in thoracic tumors: a large scale study of 1465 non-small cell lung cancer cases. Diagn. Pathol. 2015; 10; 210.
Wolff AC, Hammond MEH, Allison KH et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of american pathologists clinical practice guideline focused update. J. Clin. Oncol. 2018; 36; 2105-2122.
Pan H, Gray R, Braybrooke J et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N. Engl. J. Med. 2017; 377; 1836-1846.
Stabile LP, Davis AL, Gubish CT et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Can. Res. 2002; 62; 2141-2150.
Wei S, Said-Al-Naief N, Hameed O. Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas: a tissue microarray and pooled literature review study. Appl. Immunohistochem. Mol. Morphol. 2009; 17; 393-402.
Sun HB, Zheng Y, Ou W et al. Association between hormone receptor expression and epidermal growth factor receptor mutation in patients operated on for non-small cell lung cancer. Ann. Thorac. Surg. 2011; 91; 1562-1567.
Aleric I, Razumovic JJ, Koprivica B. Her-2/neu oncogene and estrogen receptor expression in non small cell lung cancer patients. Med. Pregl. 2012; 65; 210-215.
Provenzano E, Byrne DJ, Russell PA, Wright GM, Generali D, Fox SB. Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple-negative tumours. Histopathology 2016; 68; 367-377.
Cheng TD, Darke AK, Redman MW et al. Smoking, sex, and non-small cell lung cancer: steroid hormone receptors in tumor tissue (s0424). J. Natl. Cancer Inst. 2018; 110; 734-742.
Lund-Iversen M, Scott H, Strom EH, Theiss N, Brustugun OT, Gronberg BH. Expression of estrogen receptor-alpha and survival in advanced-stage non-small cell lung cancer. Anticancer Res. 2018; 38; 2261-2269.
Gomez-Fernandez C, Mejias A, Walker G, Nadji M. Immunohistochemical expression of estrogen receptor in adenocarcinomas of the lung: the antibody factor. Appl. Immunohistochem. Mol. Morphol. 2010; 18; 137-141.
Kawai H, Ishii A, Washiya K et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin. Cancer Res. 2005; 11; 5084-5089.
Hammond ME, Hayes DF, Dowsett M et al. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch. Pathol. Lab. Med. 2010; 134; 907-922.
Allison KH, Hammond MEH, Dowsett M et al. Estrogen and progesterone receptor testing in breast cancer: Asco/cap guideline update. J. Clin. Oncol. 2020; 38; 1346-1366.
Thompson AM, Jordan LB, Quinlan P et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the breast recurrence in tissues study (brits). Breast Cancer Res. 2010; 12; R92.
Schrijver W, Suijkerbuijk KPM, van Gils CH, van der Wall E, Moelans CB, van Diest PJ. Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis. J. Natl. Cancer Inst. 2018; 110; 568-580.
Raso MG, Behrens C, Herynk MH et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of nsclcs and correlates with egfr mutation. Clin. Cancer Res. 2009; 15; 5359-5368.
Lau SK, Chu PG, Weiss LM. Immunohistochemical expression of estrogen receptor in pulmonary adenocarcinoma. Appl. Immunohistochem. Mol. Morphol. 2006; 14; 83-87.
Bogina G, Zamboni G, Sapino A et al. Comparison of anti-estrogen receptor antibodies sp1, 6f11, and 1d5 in breast cancer: Lower 1d5 sensitivity but questionable clinical implications. Am. J. Clin. Pathol. 2012; 138; 697-702.
Chen XQ, Zheng LX, Li ZY, Lin TY. Clinicopathological significance of oestrogen receptor expression in non-small cell lung cancer. J. Int. Med. Res. 2017; 45; 51-58.
Berardi R, Morgese F, Santinelli A et al. Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex. Oncotarget 2016; 7; 82648-82657.
Mohsin SK, Weiss H, Havighurst T et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod. Pathol. 2004; 17; 1545-1554.
Nordenskjold A, Fohlin H, Fornander T, Lofdahl B, Skoog L, Stal O. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer. Breast Cancer Res. Treat. 2016; 160; 313-322.
Di Nunno L, Larsson LG, Rinehart JJ, Beissner RS. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch. Pathol. Lab. Med. 2000; 124; 1467-1470.
Ishibashi H, Suzuki T, Suzuki S et al. Progesterone receptor in non-small cell lung cancer-a potent prognostic factor and possible target for endocrine therapy. Can. Res. 2005; 65; 6450-6458.
Takeda Y, Tsuta K, Shibuki Y et al. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors. Arch. Pathol. Lab. Med. 2008; 132; 239-243.
Wells JM, Ginter PS, Liu Y, Chen Z, Narula N, Shin SJ. Evaluating the utility of trefoil factor 1 as a mammary-specific immunostain compared and in conjunction with gata-3 and mammaglobin in the distinction between carcinoma of breast and lung. Am. J. Clin. Pathol. 2015; 144; 444-451.
Hirsch FR, Varella-Garcia M, Franklin WA et al. Evaluation of her-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br. J. Cancer 2002; 86; 1449-1456.
Mazieres J, Peters S, Lepage B et al. Lung cancer that harbors an her2 mutation: epidemiologic characteristics and therapeutic perspectives. J. Clin. Oncol. 2013; 31; 1997-2003.
Hirsch FR, Suda K, Wiens J, Bunn PA Jr. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet 2016; 388; 1012-1024.
Kim EK, Kim KA, Lee CY, Shim HS. The frequency and clinical impact of her2 alterations in lung adenocarcinoma. PLoS One 2017; 12; e0171280.
Kobyakov DS, Avdalyan AM, Klimachev VV, Lazarev AF, Lushnikova EL, Nepomnyaschikh LM. non-small cell lung cancer: Her2 oncogene status. Arkh Patol. 2015; 77; 3-9.
Reis H, Herold T, Ting S et al. Her2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas. Lung Cancer 2015; 88; 34-41.
Ko YS, Kim NY, Pyo JS. Concordance analysis between her2 immunohistochemistry and in situ hybridization in non-small cell lung cancer. Int. J. Biol. Markers 2018; 33; 49-54.
Tan D, Deeb G, Wang J et al. Her-2/neu protein expression and gene alteration in stage i-iiia non-small-cell lung cancer: A study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn. Mol. Pathol. 2003; 12; 201-211.
Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 2003; 21; 3798-3807.
Liu L, Shao X, Gao W et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J. Thorac. Oncol. 2010; 5; 1922-1932.
Cimino-Mathews A, Subhawong AP, Illei PB et al. Gata3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. Hum. Pathol. 2013; 44; 1341-1349.
Ni YB, Tsang JYS, Shao MM et al. Gata-3 is superior to gcdfp-15 and mammaglobin to identify primary and metastatic breast cancer. Breast Cancer Res. Treat. 2018; 169; 25-32.
Hattori Y, Yoshida A, Yoshida M, Takahashi M, Tsuta K. Evaluation of androgen receptor and gata binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung. Pathol. Int. 2015; 65; 286-292.
Liu H, Shi J, Prichard JW, Gong Y, Lin F. Immunohistochemical evaluation of gata-3 expression in er-negative breast carcinomas. Am. J. Clin. Pathol. 2014; 141; 648-655.
Mohammed KH, Siddiqui MT, Cohen C. Gata3 immunohistochemical expression in invasive urothelial carcinoma. Urol. Oncol. 2016; 34; 432 e439-432 e413.
Miettinen M, McCue PA, Sarlomo-Rikala M et al. Gata3: A multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am. J. Surg. Pathol. 2014; 38; 13-22.
Hashiguchi T, Miyoshi H, Nakashima K et al. Prognostic impact of gata binding protein-3 expression in primary lung adenocarcinoma. Hum. Pathol. 2017; 63; 157-164.
Sauter G. Representativity of tma studies. Methods Mol. Biol. 2010; 664; 27-35.